Article Text
Statistics from Altmetric.com
Study design
Design:
randomised placebo-controlled trial (Hyperinsulinemia: the Outcome of its Metabolic Effects [HOME]). ClinicalTrials.gov NCT00375388.
Allocation:
{concealed}*.†
Blinding:
blinded (patients, clinicians, {data collectors, outcome assessors, data analysts, safety committee, and writers}*).†
Study question
Setting:
outpatient clinics of 3 hospitals in Hoogeveen, Meppel, and Coevorden, the Netherlands.
Patients:
390 patients 30–80 years of age (mean age 61 y, 54% women) who had type 2 diabetes.
Intervention:
metformin hydrochloride, 850 mg 1–3 times daily (n = 196), or matching placebo (n = 194), with insulin therapy.
Outcomes:
composite of microvascular and macrovascular disease (myocardial infarction [MI]; heart failure; acute coronary syndrome; peripheral arterial disease; sudden death; progression of retinopathy, nephropathy, or neuropathy; and 9 other items). Secondary outcomes included microvascular disease, macrovascular disease, and metabolic end points (body …
Footnotes
-
Source of funding: Altana; Lifescan; E. Merck/Santé Merck, Sharpe, & Dohme; Novo Nordisk.